Crossmark

Reply to “Rethinking screening strategies for non-obese individuals at risk for MASLD: a clinical perspective on metabolic vulnerability”

Published Online: 2026-03-09

Published Print: 2026-04

Authors

Tsutsumi, Tsubasa https://orcid.org/0000-0001-6571-9874
Kawaguchi, Takumi

Fujii, Hideki
License Information

Text and Data Mining valid from 2026-03-09

Version of Record valid from 2026-03-09
More Information

Article History

Received: 23 February 2026

Accepted: 3 March 2026

First Online: 9 March 2026

Declarations

:

: T.T. provided a consultant to Madrigal. T.K. received lecture fees from Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., ASKA Pharmaceutical Co., Ltd., AbbVie GK., and EA Pharma Co., Ltd.

Document is current